While those genes that are suppressed by overexpression of SFPQ include UBD, LGR5, PIK3IP1, GBP2, ST8SIA2, and NKAIN4. Adjunctive GH1 therapy as nutritional augmentation in children with cystic fibrosis is in phase 3 clinical trial as it significantly improves height, weight, bone mineral content, lean tissue mass, and decreased number of hospitalizations35–39. The gene discussed is GH1; the disease is cystic fibrosis.